Zum Inhalt springen


  1. Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273-288.
  2. European Medicines Agency. Luxturna. https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna. Accessed November 5, 2021.
  3. European Medicines Agency. Zolgensma. https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma. Accessed November 5, 2021.
  4. Food and Drug Administration. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. Accessed November 5, 2021.
  5. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-464.
  6. Mccain J. The Future of Gene Therapy. Biotechnol Healthc. 2005;2(3):52-54,56-60.
  7. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science. 1972;175(4025):949-955. doi:10.1126/science. 175.4025.949
  8. Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101(7):2563-2569.
  9. Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. [press release]. Silver Spring, Maryland, USA: US Food and Drug Administration (FDA). https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics. Published January 15, 2019. Accessed November 5, 2021.
  10. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral vector systems for gene therapy: a comprehensive liverature reveiw of progress and biosafety challenges. Appl Biosaf. 2020;25(1):7-18.
  11. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee Meeting #70. Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy (GT). Published September 2021.
  12. Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2019;2019(1):1-8.
  13. American Society of Gene and Cell Therapy (ASGCT) and PharmaInteligence. Q3 2021 Quarterly Data Report on Gene, Cell, & RNA Therapy Landscape. Accessed December 1, 2021.
  14. European Medicines Agency. Imlygic. https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic. Accessed November 5, 2021.
  15. European Medicines Agency. Strimvelis. https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis. Accessed November 5, 2021.
  16. European Medicines Agency. Kymriah. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah. Accessed November 5, 2021.
  17. European Medicines Agency. Yescarta. https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta. Accessed November 5, 2021.
  18. European Medicines Agency. Zynteglo. https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo. Accessed November 5, 2021.
  19. European Medicines Agency. Tecartus. https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus. Accessed November 5, 2021.
  20. European Medicines Agency. Libmeldy. https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy. Accessed November 5, 2021.
  21. European Medicines Agency. Abecma. https://www.ema.europa.eu/en/medicines/human/EPAR/abecma. Accessed November 5, 2021.
  22. European Medicines Agency. Skysona. https://www.ema.europa.eu/en/medicines/human/EPAR/skysona. Accessed November 5, 2021.
  23. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene thearpy delivery. Nat Rev Drug Discov. 2019;18(5):358-378.
  24. Bak RO, Gomez-Ospina N, Porteus MH, Gene Editing on Center Stage. Trends Genet. 2018;34(8):600-611.
  25. Ledford H, Callaway E. Pioneers of crispr gene editing win chemistry Nobel. Nature. 2020;586:346-347.
  26. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VII Gene Transfer in Severe Hemophilia A. N Engl J Med. 2017;377(26):2519-2530.
  27. Thomas KR, Folger KR, Capecchi MR. High frequency targeting of genes to specific sites in the mammalian genome. Cell. 1986;44:419-428.
  28. Boston Children’s Hospital. After decades of evolution, gene therapy arrives. https://answers.childrenshospital.org/gene-therapy-history/. Published December 22, 2020. Accessed November 17, 2021.
  29. Arruda V, Stedman H, Jian H, et al. Correction of hemophilia B phenotype by novel method of regional intravenous delivery of AAV vector to skeletal muscle of hemophilia B dogs. Mol Ther. 2005;11:S233.
  30. European Medicines Agency recommends first gene therapy for approval [press release]. London, England: European Medicines Agency (EMA). https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-first-gene-therapy-approval. Published July 20, 2012. Accessed November 5, 2021.
  31. FDA approval brings first gene therapy to the United States [press release]. Silver Spring, Maryland, USA: US Food and Drug Administration (FDA). https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states. Published August 30, 2017. Accessed November 5, 2021. 1Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273-288.
  32. European Medicines Agency. Glyberta. https://www.ema.europa.eu/en/medicines/human/EPAR/glybera. Accessed November 5, 2021.
  33. First gene therapy for treat severe haemophilia A [press release]. London, England: European Medicines Agency (EMA). https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia. Published June 24, 2022. Accessed June 24, 2022.